橋本病を伴った全身性強皮症 Systemic Sclerosis Associated with Hashimoto Disease

この論文にアクセスする

この論文をさがす

著者

抄録

当科にて加療中の全身性強皮症患者59例を対象として,橋本病の合併について検討した.全身性強皮症59例中23例(39.0%)と高率に橋本病の合併を認め,病型別ではDiffuse type 19例中9例(47.4%),Limited type 40例中14例(35.0%)であった.特にシェーグレン症候群を合併した全身性強皮症29例中の橋本病合併は14例(48.3%)と高頻度に認められた.橋本病合併群は橋本病非合併群と比較し,顔面の皮膚硬化が強い傾向を認め,とりわけ甲状腺機能低下群は有意に顔面の皮膚硬化が強かった.従って,顔面の皮膚硬化の強い症例に橋本病合併が高い傾向が見られ,なかでも甲状腺機能低下例は,明らかに顔面の皮膚硬化と関連していると思われた.これまで全身性強皮症の橋本病の合併は,Limited type,女性例,シェーグレン症候群合併例に多いとされていたが,今回の我々の検討では,むしろ,Diffuse type,顔面のスキンスコア高値例に橋本病合併が多い傾向が認められた.全身性強皮症患者では,橋本病合併の頻度が高いため,ルーチンに抗甲状腺抗体の検査をすべきと考えられた.

We studied 59 patients with systemic sclerosis (SSc) to evaluate their association with Hashimoto disease. Hashimoto disease occurred in 23 of these 59 patients (39.0%). Of the 19 patients with diffuse-type SSc and the 40 patients with limited-type SSc, 9 (47.4%) and 14 (35.0%), respectively, had Hashimoto disease. Of the 29 patients in whom SSc coexisted with Sjögren's syndrome, 14 (48.3%) had Hashimoto disease. The patients with both SSc and Hashimoto disease were more likely to have facial scleroderma than the patients without Hashimoto disease. Additionally, among patients with both SSc and hypothyroidism, those with Hashimoto disease had statistically significantly more severe facial scleroderma than those who did not have Hashimoto disease. Thus, we observed a high tendency of association between Hashimoto disease and severe facial scleroderma. Also, it appeared that hypothyroidism was clearly associated with facial scleroderma. We recommend routine testing for antithyroid antibodies in patients with SSc, because of the possible association between these factors and Hashimoto disease.

収録刊行物

  • 日本皮膚科学会雑誌

    日本皮膚科学会雑誌 112(3), 233-238, 2002-03-20

    Japanese Dermatological Association

参考文献:  28件中 1-28件 を表示

各種コード

  • NII論文ID(NAID)
    10008584493
  • NII書誌ID(NCID)
    AN00196602
  • 本文言語コード
    JPN
  • 資料種別
    ART
  • ISSN
    0021499X
  • NDL 記事登録ID
    025120573
  • NDL 請求記号
    Z19-202
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ